Tactile Systems Technology Inc is a medical technology company... Show more
The Moving Average Convergence Divergence (MACD) for TCMD turned positive on September 10, 2026. Looking at past instances where TCMD's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TCMD's RSI Indicator exited the oversold zone, 21 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on TCMD as a result. In 77 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
Following a +1.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where TCMD advanced for three days, in 212 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
TCMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 62 cases where TCMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
The 50-day moving average for TCMD moved below the 200-day moving average on September 08, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for TCMD entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. TCMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.300) is normal, around the industry mean (10.865). P/E Ratio (21.243) is within average values for comparable stocks, (98.603). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (11.050). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.458) is also within normal values, averaging (39.828).
The Tickeron SMR rating for this company is 64 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a medical devices developer
Industry MedicalNursingServices